Table 3.
General characteristics of the selected studies.
| Study, author and year | Study design | Number of patients | Number of smokers | Number of females | Number of IBDs included (n) | Age, mean & range (years) | Intervention and number of IBDs analysed |
Follow-up(weeks) | Main outcome at follow up | |
|---|---|---|---|---|---|---|---|---|---|---|
| Test(n) | Control(n) | |||||||||
| Pradeep et al. (2013) | RCT | 41 | 0 | 21 | 118 | 37.2 (30–50) |
0.5% MF (26), 1% MF (27), 1.5% MF (29) | SRP + 0% MF (26) | 6 months | Clinical and radiographic parameters were significantly better in test groups than control. 1% MF provided highest improvement |
| Rao et al. (2013) | RCT | 50 | 50 | 0 | 71 | 34.6 (30–50) | 1% MF (36) | SRP + 0% MF (35) | 6 months | Clinical parameters and radiographic were significantly better in test groups than control |
| Pradeep et al. (2016) | RCT | 65 | 0 | 38 | 65 | 32.4 (25–50) | 1% MF (33) | SRP + 0% MF (32) | 6 months | Clinical parameters and radiographic were significantly better in test groups than control |
| Pradeep et al. (2015) | RCT | 120 | 0 | 68 | 120 | 41 (30–50) | OFD + PRF (30), OFD + 1% MF (30), OFD + PRF + 1%MF (30) | OFD (30) | 9 months | Clinical parameters and radiographic were significantly better in test groups than control. OFD + PRF+1% MF provided highest improvement |
IBDs, intrabony defects; MF, metformin gel; OFD, open-flap debridement; PRF, platelet-rich fibrin; RCT, randomized control trial; SRP, scaling and root planing.